financetom
Business
financetom
/
Business
/
Neo Performance Materials Q1 Adjusted Net Income Boosted By Better Than Expected Revs; Lifts Its 2026 Adjusted EBITDA Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neo Performance Materials Q1 Adjusted Net Income Boosted By Better Than Expected Revs; Lifts Its 2026 Adjusted EBITDA Outlook
May 12, 2026 5:35 AM

08:14 AM EDT, 05/12/2026 (MT Newswires) -- Neo Performance Materials ( NOPMF ) , trading at 52 week highs, on Tuesday said its adjusted net income for the first quarter more than doubled, boosted by better than expected revenues, while increasing its 2026 Adjusted EBITDA outlook

Adjusted Net Income for Q1 2026 was US$14.9 million, or $0.36 earnings per share, compared to Adjusted Net Income of $6.5 million or $0.15 earnings per share for Q1 2025. Commencing this quarter, Neo is revising the calculation of Adjusted Net Income to better reflect underlying operating performance attributable to Neo shareholders and improve comparability across periods.

Revenue for Q1 2026 was $155.0 million, compared to $121.6 million for Q1 2025 and beating a consensus forecast at FactSet of $127.3 million.

Adjusted EBITDA for Q1 2026 was $36.2 million versus $17.1 million for Q1 2025. This resulted in Adjusted EBITDA margin of 23.4% for the quarter, representing an improvement of 930 BPS over 2025.

Neo has increased its 2026 Adjusted EBITDA outlook to $100 million to $110 million (up from $75 to $80 million) based on strong first quarter performance, supportive pricing conditions across the critical materials portfolio, improved demand visibility driven by customer contracting activity, and disciplined operational execution.

Rahim Suleman, President and Chief Executive Officer, said: "We saw both strong demand and strong pricing across all three business units and all business units improved year over year. Our Rare Metals business, which focusses on critical materials such as hafnium and gallium contributed meaningfully to earnings growth. We advanced key strategic milestones, including the production of our one-millionth magnet at our European Permanent Magnet facility, and the commissioning of our new small scale heavy rare earth separation production line in Silmet, a critical step in our strategy to build the most vertically integrated rare earth magnetics value chain in Europe."

Suleman added: "Given our strong first-quarter performance, healthy demand outlook and continued favourable pricing environment, we are raising our full-year Adjusted EBITDA guidance to a range of $100 million to $110 million. As global supply chains increasingly prioritize security and localization of critical materials, and structural growth drivers including AI infrastructure, electrification, automation and aerospace continue to underpin a supportive demand environment, Neo is well positioned for the future. Looking ahead, we remain focused on delivering disciplined growth, strong execution and long-term value for our stakeholders."

Shares in NEO rose $0.56 or 1.9% to $29.64 in Canada yesterday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
Jun 23, 2025
LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly's ( LLY ) pipeline. Novo on Sunday said full results from two late-stage trials of CagriSema - one in people with obesity or overweight, the other in...
PTC Therapeutics Says European Commission Grants it Marketing Authorization for Sephience
PTC Therapeutics Says European Commission Grants it Marketing Authorization for Sephience
Jun 23, 2025
07:48 AM EDT, 06/23/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Monday the European Commission has granted marketing authorization for Sephience to treat children and adults with phenylketonuria. The approval is based on results from the phase 3 APHENITY trial and the APHENITY long-term extension study, the company said. The marketing authorization applies to all 27 European Union...
Global Medical REIT Appoints Mark Decker Jr. Chief Executive
Global Medical REIT Appoints Mark Decker Jr. Chief Executive
Jun 23, 2025
07:48 AM EDT, 06/23/2025 (MT Newswires) -- Global Medical REIT ( GMRE ) said Monday its board has appointed Mark Decker Jr. as chief executive officer and president, effective immediately. Decker, who also joins the company's board, succeeds Jeffrey Busch, who will remain as non-executive chairman. Decker most recently led the net lease real estate investment strategy at Proterra Investment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved